Advertisement

Hepatitis C: Shorter Course Possible with Sofosbuvir; ABT-450/r Combo Seen Effective — Physician’s First Watch

Medical News |
April 11, 2014

Hepatitis C: Shorter Course Possible with Sofosbuvir; ABT-450/r Combo Seen Effective

By Joe Elia

Sofosbuvir therapy for hepatitis C, criticized for its cost, could be shortened from 12 weeks to 8, according to a randomized, phase III study presented at the International Liver Congress and published in the New England Journal of Medicine. In other phase III studies in NEJM, a combination of drugs was effective both in previously treated as well as untreated patients with hepatitis C. The studies were conducted by the drug makers.

In the sofosbuvir study, an 8-week course including ledipasvir was not inferior to a 12-week course, or to an 8-week course that also added ribavirin. All regimens showed a sustained virologic response rate of roughly 95% at 12 weeks after the completion of therapy.

Another research group studied the combination of a protease inhibitor (ABT-450) and a drug that delays its degradation (ritonavir), plus two inhibitors of hepatitis C virus replication (ombitasvir and dasabuvir). By 12 weeks after treatment completion, combination therapy had produced a sustained virologic response rate of roughly 95% both in patients previously treated with other drugs and in those previously untreated.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement